Here are six things to know.
1. Evoke will submit a New Drug Application for its lead product candidate, Gimoti.
2. Gimoti is a metoclopramide nasal spray intended for female patients with acute and recurrent diabetic gastroparesis.
3. Metoclopramide is the only product currently approved in the U.S. to treat gastroparesis, and is currently available only orally and intravenously. Gimoti is designed to provide metoclopramide delivery through intranasal administration to avoid gastric absorption issues.
4. Evoke Pharma Chairman Cam L. Garner and President and CEO David A. Gonyer, RPh, co-founded the company in 2007.
5. The company’s cash and cash equivalents were approximately $7.7 million as of Dec. 31, 2017.
6. For the fourth quarter of 2017, net loss was approximately $308,000, compared to a net loss of approximately $1.5 million for the fourth quarter of 2016. According to Mr. Gonyer, Evoke Pharma has cash runway into January 2019 and is actively evaluating multiple strategic partnerships for Gimoti, including debt financing and other potential partnerships.
More articles on gastroenterology:
4 things to know about Pentax Medical USA
GI leader to know: Dr. Paul Yeaton of Carilion Clinic
AGA names Dr. Michael Kaczanowski a fellow — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.